AKBA vs. SNOA

Last updated Apr 2, 2026

Compare and contrast key facts about Akebia Therapeutics, Inc. (AKBA) and Sonoma Pharmaceuticals, Inc. (SNOA).

Performance

AKBA vs. SNOA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Akebia Therapeutics, Inc. (AKBA) and Sonoma Pharmaceuticals, Inc. (SNOA). The values are adjusted to include any dividend payments, if applicable.

AKBA vs. SNOA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
AKBA Akebia Therapeutics, Inc.	-12.42%	-15.26%	53.23%	114.90%	-74.47%	-19.29%	-55.70%	14.29%	-62.81%	42.84%
SNOA Sonoma Pharmaceuticals, Inc.	-33.24%	35.32%	-25.44%	-83.89%	-75.44%	-37.19%	66.51%	-32.01%	-86.93%	8.13%

Fundamentals

Market Cap AKBA : $374.17M SNOA : $4.16M
EPS AKBA : -$0.02 SNOA : -$2.02
PS Ratio AKBA : 1.61 SNOA : 0.23
PB Ratio AKBA : 11.47 SNOA : 1.21
Total Revenue (TTM) AKBA : $236.19M SNOA : $17.72M
Gross Profit (TTM) AKBA : $196.73M SNOA : $6.76M
EBITDA (TTM) AKBA : $19.26M SNOA : -$3.06M

Returns By Period

In the year-to-date period, AKBA achieves a -12.42% return, which is significantly higher than SNOA's -33.24% return. Over the past 10 years, AKBA has outperformed SNOA with an annualized return of -17.19%, while SNOA has yielded a comparatively lower -44.24% annualized return.

AKBA

• 1D: 1.44%
• 1M: 11.90%
• YTD: -12.42%
• 6M: -47.39%
• 1Y: -26.18%
• 3Y*: 36.01%
• 5Y*: -15.79%
• 10Y*: -17.19%

SNOA

• 1D: 14.08%
• 1M: -14.44%
• YTD: -33.24%
• 6M: -37.05%
• 1Y: 11.98%
• 3Y*: -50.07%
• 5Y*: -57.54%
• 10Y*: -44.24%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AKBA vs. SNOA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AKBA

AKBA Risk / Return Rank: 27
AKBA Sharpe Ratio Rank: 24
AKBA Sortino Ratio Rank: 27
AKBA Omega Ratio Rank: 27
AKBA Calmar Ratio Rank: 28
AKBA Martin Ratio Rank: 30

SNOA

SNOA Risk / Return Rank: 52
SNOA Sharpe Ratio Rank: 43
SNOA Sortino Ratio Rank: 69
SNOA Omega Ratio Rank: 61
SNOA Calmar Ratio Rank: 44
SNOA Martin Ratio Rank: 44

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AKBA vs. SNOA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Akebia Therapeutics, Inc. (AKBA) and Sonoma Pharmaceuticals, Inc. (SNOA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AKBA	SNOA	Difference
Sharpe ratio Return per unit of total volatility	-0.36	0.10	-0.47
Sortino ratio Return per unit of downside risk	-0.05	1.57	-1.62
Omega ratio Gain probability vs. loss probability	0.99	1.17	-0.17
Calmar ratio Return relative to maximum drawdown	-0.38	0.18	-0.56
Martin ratio Return relative to average drawdown	-0.62	0.35	-0.97
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AKBA vs. SNOA - Sharpe Ratio Comparison

The current AKBA Sharpe Ratio is -0.36, which is lower than the SNOA Sharpe Ratio of 0.10. The chart below compares the historical Sharpe Ratios of AKBA and SNOA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	AKBA	SNOA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.36	0.10	-0.47
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.17	-0.49	+0.32
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.20	-0.43	+0.23
Sharpe Ratio (All Time) Calculated using the full available price history	-0.26	-0.33	+0.07

Correlation

The correlation between AKBA and SNOA is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

AKBA vs. SNOA - Dividend Comparison

Neither AKBA nor SNOA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

AKBA vs. SNOA - Drawdown Comparison

The maximum AKBA drawdown since its inception was -99.14%, roughly equal to the maximum SNOA drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for AKBA and SNOA.

Drawdown Indicators

	AKBA	SNOA	Difference
Max Drawdown Largest peak-to-trough decline	-99.14%	-100.00%	+0.86%
Max Drawdown (1Y) Largest decline over 1 year	-70.57%	-61.31%	-9.26%
Max Drawdown (5Y) Largest decline over 5 years	-94.05%	-98.97%	+4.92%
Max Drawdown (10Y) Largest decline over 10 years	-98.73%	-99.87%	+1.14%
Current Drawdown Current decline from peak	-95.17%	-100.00%	+4.83%
Average Drawdown Average peak-to-trough decline	-77.04%	-91.08%	+14.04%
Ulcer Index Depth and duration of drawdowns from previous peaks	42.52%	31.52%	+11.00%

Volatility

AKBA vs. SNOA - Volatility Comparison

The current volatility for Akebia Therapeutics, Inc. (AKBA) is 14.87%, while Sonoma Pharmaceuticals, Inc. (SNOA) has a volatility of 25.98%. This indicates that AKBA experiences smaller price fluctuations and is considered to be less risky than SNOA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AKBA	SNOA	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.87%	25.98%	-11.11%
Volatility (6M) Calculated over the trailing 6-month period	60.07%	41.15%	+18.92%
Volatility (1Y) Calculated over the trailing 1-year period	72.07%	119.18%	-47.11%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	90.73%	117.80%	-27.07%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	84.10%	103.01%	-18.91%

Financials

AKBA vs. SNOA - Profitability Comparison

The chart below illustrates the profitability comparison between Akebia Therapeutics, Inc. and Sonoma Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

AKBA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Akebia Therapeutics, Inc. reported a gross profit of 45.41M and revenue of 57.62M. Therefore, the gross margin over that period was 78.8%.

SNOA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Sonoma Pharmaceuticals, Inc. reported a gross profit of 1.65M and revenue of 4.35M. Therefore, the gross margin over that period was 37.9%.

AKBA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Akebia Therapeutics, Inc. reported an operating income of -8.55M and revenue of 57.62M, resulting in an operating margin of -14.8%.

SNOA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Sonoma Pharmaceuticals, Inc. reported an operating income of -678.00K and revenue of 4.35M, resulting in an operating margin of -15.6%.

AKBA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Akebia Therapeutics, Inc. reported a net income of -12.24M and revenue of 57.62M, resulting in a net margin of -21.3%.

SNOA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Sonoma Pharmaceuticals, Inc. reported a net income of -819.00K and revenue of 4.35M, resulting in a net margin of -18.8%.